Brokerages forecast that Voyager Therapeutics Inc (NASDAQ:VYGR) will post ($0.74) earnings per share for the current quarter, according to Zacks. Four analysts have made estimates for Voyager Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.92) and the highest estimate coming in at ($0.48). Voyager Therapeutics reported earnings of ($0.57) per share in the same quarter last year, which would indicate a negative year over year growth rate of 29.8%. The company is expected to issue its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Voyager Therapeutics will report full-year earnings of ($3.00) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.74). For the next financial year, analysts expect that the firm will post earnings of ($3.25) per share, with EPS estimates ranging from ($4.16) to ($1.98). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Voyager Therapeutics.
Several analysts recently weighed in on the company. Stifel Nicolaus restated a “buy” rating and set a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Cowen restated a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, October 31st. ValuEngine lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Piper Jaffray Companies restated an “overweight” rating and set a $28.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 28th. Finally, Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $26.33.
A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Voyager Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after purchasing an additional 13,194 shares during the period. Wells Fargo & Company MN grew its position in shares of Voyager Therapeutics by 312.8% during the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after buying an additional 285,806 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Voyager Therapeutics during the 3rd quarter worth $5,155,000. DAFNA Capital Management LLC grew its position in shares of Voyager Therapeutics by 187.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after buying an additional 133,488 shares in the last quarter. Finally, State Street Corp grew its position in shares of Voyager Therapeutics by 11.8% during the 2nd quarter. State Street Corp now owns 184,526 shares of the company’s stock worth $1,653,000 after buying an additional 19,471 shares in the last quarter. Institutional investors and hedge funds own 35.97% of the company’s stock.
Shares of Voyager Therapeutics (NASDAQ VYGR) opened at $14.03 on Tuesday. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $25.99.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.